a50725085.htm


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

 
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
 
For the month of October 8, 2013
 
Commission File Number 001-16174

 
TEVA PHARMACEUTICAL INDUSTRIES LIMITED
(Translation of registrant’s name into English)

 
5 Basel Street, P.O. Box 3190
Petach Tikva 4951033 Israel
(Address of principal executive offices)

 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
 
Form 20-F  x            Form 40-F  ¨
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
 


 
 
 

 
 
CONTENTS
 
 This Report on Form 6-K consists of the following document[s], which [is/are] attached hereto and incorporated by reference herein:
 
99.1
Teva R&D in Focus - Respiratory Webinar Presentation
 
 
 

 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
 
TEVA PHARMACEUTICAL INDUSTRIES LIMITED
   
     
Date: Oct. 9, 2013
By:
/S/    EYAL DESHEH
 
Name:
Eyal Desheh
 
Title:
Group Executive Vice President, Chief Financial Officer
 
 
 

 
 
EXHIBIT INDEX

Exhibit No.
 
Description
     
99.1
 
Teva R&D in Focus – Respiratory Webinar Presentation